AIM ImmunoTech Inc
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for … Read more
AIM ImmunoTech Inc (AIM) - Total Assets
Latest total assets as of March 2025: $6.25 Million USD
Based on the latest financial reports, AIM ImmunoTech Inc (AIM) holds total assets worth $6.25 Million USD as of March 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
AIM ImmunoTech Inc - Total Assets Trend (1995–2024)
This chart illustrates how AIM ImmunoTech Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
AIM ImmunoTech Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
AIM ImmunoTech Inc's total assets of $6.25 Million consist of 48.5% current assets and 51.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.59 Million | 30.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1995–2024)
This chart illustrates how AIM ImmunoTech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AIM ImmunoTech Inc's current assets represent 48.5% of total assets in 2024, a decrease from 89.8% in 1995.
- Cash Position: Cash and equivalents constituted 19.8% of total assets in 2024, down from 89.0% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 30.0% of total assets, an increase from 9.0% in 1995.
- Asset Diversification: The largest asset category is intangible assets at 30.1% of total assets.
AIM ImmunoTech Inc Competitors by Total Assets
Key competitors of AIM ImmunoTech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
AIM ImmunoTech Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - AIM ImmunoTech Inc generates 0.02x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - AIM ImmunoTech Inc is currently not profitable relative to its asset base.
AIM ImmunoTech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.26 | 1.14 | 33.66 |
| Quick Ratio | 0.26 | 1.14 | 33.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-7.18 Million | $ 1.43 Million | $ 44.68 Million |
AIM ImmunoTech Inc - Advanced Valuation Insights
This section examines the relationship between AIM ImmunoTech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.72 |
| Latest Market Cap to Assets Ratio | 0.72 |
| Asset Growth Rate (YoY) | -55.6% |
| Total Assets | $8.61 Million |
| Market Capitalization | $6.23 Million USD |
Valuation Analysis
Below Book Valuation: The market values AIM ImmunoTech Inc's assets below their book value (0.72 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: AIM ImmunoTech Inc's assets decreased by 55.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for AIM ImmunoTech Inc (1995–2024)
The table below shows the annual total assets of AIM ImmunoTech Inc from 1995 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $8.61 Million | -55.59% |
| 2023-12-31 | $19.38 Million | -52.13% |
| 2022-12-31 | $40.49 Million | -29.83% |
| 2021-12-31 | $57.70 Million | -10.66% |
| 2020-12-31 | $64.58 Million | +219.42% |
| 2019-12-31 | $20.22 Million | +46.04% |
| 2018-12-31 | $13.85 Million | -2.55% |
| 2017-12-31 | $14.21 Million | -24.72% |
| 2016-12-31 | $18.87 Million | -17.24% |
| 2015-12-31 | $22.80 Million | -22.54% |
| 2014-12-31 | $29.44 Million | -7.62% |
| 2013-12-31 | $31.87 Million | -44.77% |
| 2012-12-31 | $57.70 Million | +32.60% |
| 2011-12-31 | $43.51 Million | -15.80% |
| 2010-12-31 | $51.68 Million | -20.48% |
| 2009-12-31 | $64.99 Million | +391.97% |
| 2008-12-31 | $13.21 Million | -42.91% |
| 2007-12-31 | $23.14 Million | -26.37% |
| 2006-12-31 | $31.43 Million | +27.40% |
| 2005-12-31 | $24.67 Million | -1.99% |
| 2004-12-31 | $25.17 Million | +87.79% |
| 2003-12-31 | $13.40 Million | +121.92% |
| 2002-12-31 | $6.04 Million | -49.81% |
| 2001-12-31 | $12.04 Million | -7.90% |
| 2000-12-31 | $13.07 Million | -7.98% |
| 1999-12-31 | $14.20 Million | -12.88% |
| 1998-12-31 | $16.30 Million | +41.74% |
| 1997-12-31 | $11.50 Million | +64.29% |
| 1996-12-31 | $7.00 Million | -44.88% |
| 1995-12-31 | $12.70 Million | -- |